Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
CB1 receptor agonists
JWH-363
Другие языки:

    JWH-363

    Подписчиков: 0, рейтинг: 0
    JWH-363
    JWH-363.svg
    Legal status
    Legal status
    Identifiers
    • 1-Naphthyl{1-pentyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanone
    CAS Number
    PubChem CID
    ChemSpider
    Chemical and physical data
    Formula C27H24F3NO
    Molar mass 435.490 g·mol−1
    3D model (JSmol)
    • CCCCCN1C=C(C=C1C2=CC(=CC=C2)C(F)(F)F)C(=O)C3=CC=CC4=CC=CC=C43
    • InChI=1S/C27H24F3NO/c1-2-3-6-15-31-18-21(17-25(31)20-11-7-12-22(16-20)27(28,29)30)26(32)24-14-8-10-19-9-4-5-13-23(19)24/h4-5,7-14,16-18H,2-3,6,15H2,1H3 checkY
    • Key:GETLFVZYXNFVJS-UHFFFAOYSA-N checkY

    JWH-363 (1-Naphthyl{1-pentyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 245 ± 5nM) and CB2 (Ki = 71 ± 1nM) receptors, with a moderate (~3.45x) selectivity for the latter. JWH-363 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.

    Legality

    In the United States JWH-363 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-363.

    In Canada, JWH-363 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.

    In the United Kingdom, JWH-363 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.

    See also



    Новое сообщение